Moleculin Q3 2023 Earnings Report
Key Takeaways
Moleculin Biotech reported its financial results for the quarter ended September 30, 2023, with $24.6 million in cash and cash equivalents. The company believes that this cash is sufficient to meet its planned operations into the third quarter of 2024.
Dosed first subjects in Phase 2 portion of the clinical trial evaluating Annamycin in combination with Cytarabine (Ara-C) for the treatment of Acute Myeloid Leukemia (AML) (MB106).
Completed enrollment in U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB107).
Announced a new positive independent assessment report was published confirming the absence of cardiotoxicity in subjects treated with Annamycin.
Presented poster at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland.
Moleculin
Moleculin
Forward Guidance
Moleculin believes that its cash is sufficient to meet its planned operations, which include the current Phase 2 clinical programs and preparations for future clinical trials, into the third quarter of 2024.